Bristol's Breyanzi, Off To A ‘Good Start,’ Shows Efficacy In Earlier Lymphoma Setting
Executive Summary
The CAR-T therapy met the primary endpoint of improvement in event-free survival in a Phase III trial evaluating Breyanzi as a second-line alternative to stem cell transplant in large B-cell lymphoma.
You may also be interested in...
Yescarta, Breyanzi Offer Practice-Changing Options For Second-Line LBCL
Data at ASH show CAR-T therapies may replace standard of care in an earlier line of large B-cell lymphoma with similar response rates and event-free survival for Kite’s established Yescarta and Bristol’s newer Breyanzi.
BMS Makes The Case For A Lasting Hematology Legacy
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.
Bristol’s Bold Projections Grow Bolder As Confidence In R&D Programs Rises
Loss of exclusivity for key Bristol Myers Squibb products, starting with top seller Revlimid, is looming over the company’s R&D pipeline. BMS believes its late-stage and newly approved products will generate more than $25bn in sales by 2029.